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Platelets play a fundamental role in pathological events underlying acute 
coronary syndrome (ACS). We present an analysis of the platelet proteome of ACS 
patients compared to matched chronic controls. The objective was to identify 
differentially regulated proteins that could provide novel information on the molecular 
mechanisms associated with the onset of the acute episode. 
In a first study, we compared the platelet proteome of 18 patients with non-ST 
segment elevation (NSTE)-ACS versus a control group consisting of 10 matched stable 
coronary artery disease (SCAD) patients. In a second study, platelets from a group of 11 
patients with ST-segment elevation (STE)-ACS were compared with a matched control 
group of 15 SCAD patients. In both cases, samples were obtained at three time points: 
on admission to hospital, after 5 days and after 6 months. Proteins were separated by 
high-resolution-2-DE and identified by MALDI-TOF/TOF. Validations were carried out 
by 1D and 2-DE western blotting. Interactions among all proteins identified were 
investigated with the Ingenuity Pathways Analysis software. 
Fluorescent staining with Sypro Ruby allowed the detection of over 2,300 spots 
per gel. After comparative analysis between ACS and SCAD controls, we found 40 
differentially regulated protein features in the case of NSTE-ACS, and 56 in the case of 
STE-ACS patients. Significant differences decreased over time, supporting the idea of 
enhanced platelet activation during the acute event. Many of the differentially regulated 
proteins identified are involved in platelet activation by integrin αIIbβ3 and/or GPVI 
receptors (e.g. CrkL, GADS, ILK, SKAP-HOM, Src, talin-1). Most differences were 
due to post-translational modifications. Interestingly, the adapter protein CrkL was 
found to be up-regulated in STE-ACS patients compared to stable controls. In 
conclusion, the present study provides novel information on platelet proteome changes 
associated with platelet activation in ACS, highlighting the involvement of proteins 
implicated in αIIbβ3 and GPVI signalling. 
